Brigatinib
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 560 publications
Expert consensus on iruplinalkib for the treatment of ALK-positive non-small cell lung cancer (2026 edition)
Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]
Published: July 25, 2026
Cost of managing brain metastases in patients with ALK+ advanced NSCLC with first-line tyrosine kinase inhibitors in the UK.
Journal: Lung cancer management
Published: July 21, 2026
Brigatinib-based targeted drug conjugates afford selective and potent anti-tumor efficacy in the treatment of pancreatic ductal adenocarcinoma.
Journal: Bioorganic chemistry
Published: June 08, 2026
Physiologically based pharmacokinetic model of two ALK inhibitors to inform drug and dosing regimens for brain metastasis patients.
Journal: Frontiers in pharmacology
Published: June 06, 2026
HPLC-MS Quantification of Multiple Tyrosine Kinase Inhibitors in Patients with Solid Tumors: Method Validation and Clinical Application.
Journal: Pharmaceutics
Published: June 05, 2026
Autoimmune pulmonary alveolar proteinosis induced by brigatinib: a case report and literature review
Autoimmune pulmonary alveolar proteinosis induced by brigatinib: a case report and literature review
Journal: Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
Published: June 03, 2026
Multiclass Machine Learning-Based Discovery of Novel Scaffold Inhibitors Targeting ALK.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: May 21, 2026
Clinical Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitors for the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer Based on the 2nd Edition of China's Drug Evaluation and Selection Guideline.
Journal: Drug design, development and therapy
Published: May 10, 2026
In silico evaluation of bioactive compounds as dual inhibitors targeting ALK and EGFR for non-small cell lung cancer therapy.
Journal: Computational biology and chemistry
Published: May 09, 2026
Autopsy-Confirmed Giant Pleural Hematoma Due to Spontaneous Hemothorax in ALK-Rearranged and TP53-Mutant Lung Adenocarcinoma: A Case Report.
Journal: OncoTargets and therapy
Published: April 17, 2026
Last Updated: 09/26/2026